

E
29. (Amended) A recombinant expression plasmid for producing human fibroblast β_1 interferon, comprising a DNA sequence coding for human fibroblast β_1 interferon operably linked therein for expression by an Escherichia coli host, whereby expression of human fibroblast β_1 interferon by [a] said host is enabled.

Claim 51, line 1, change "A host cell" to -- An *Escherichia coli* host --

Claim 52, line 3, change "a host cell" to -- *Escherichia coli*.

Claim 56, line 1, change "A" to -- An *Escherichia coli* host --;

line 4 of the sequence, change "CAT" to -- GAT --.

Please add the following new claims:

-- 60. A recombinant expression plasmid for producing human fibroblast β_1 interferon, comprising a DNA sequence for human fibroblast β_1 interferon operably linked therein for expression by a eukaryotic host cell, whereby expression of human fibroblast β_1 interferon by said eukaryotic host is enabled. --

-- 61. A eukaryotic host cell capable of expressing human fibroblast β_1 interferon polypeptide, transformed with an expression plasmid of claim 60. --

-- 62. A method of producing human fibroblast β_1 interferon polypeptide, comprising expressing the expression plasmid of claim 60 in a eukaryotic host cell. --

REMARKS

The claims have been amended to define Applicants' invention with the particularity required by statute. Claims 53, 54, 58 and 59, withdrawn from consideration as being directed to a non-elected invention, are hereby cancelled. These claims are subject of a co-pending divisional application.

Claim 50 has been cancelled in view of the Examiner's rejection of claims 49 and 50 as being duplicative. Furthermore, claims 31, 55, 56 and 57 have been amended to correct the typographical error appearing in line 4 of each sequence. Applicants greatly appreciate the Examiner calling this error to their attention so that it may be corrected.

Claims 49-52 and 55-57 stand rejected under 35 USC § 112 as broader than the enabling disclosure. The Examiner contends that the instant application does not enable the expression of β_1 interferon in any and all hosts or any and all host cells. In response, Applicants have amended the claims to specify that the host cells and hosts